LYPD3 and breast carcinoma: They showed that inhibiting the activity of this pathway with blocking antibodies against LYPD3 or AGR2 inhibited the growth of endocrine therapy resistant breast cancer in the preclinical model, and again provided the basis for the development of humanized antibodies against AGR2.